Investing for a Coronavirus Cure 🔬

Table of Contents

Investing for a Coronavirus Cure 

If and when vaccines are commercialized, stocks will hit the roof. There’s mad money waiting for savior stocks, and investors are already fishing for them with an ethical urge to back the businesses working to save the world!

It takes millions in cash burn before a jackpot drug eventually gets approved for sale, so investors are very important in biotech. You need an investor to pay for your lab experiments, and urgently. It makes sense to skip exchange requirements and go the backdoor route to market (reverse merging into a shell company– DraftKings did that!).

Your progress in the lab affects your stock price. You can keep going if you can keep investors interested in you, raising cash by issuing new shares at strong market levels. The new shares dilute the old shares, though, making them less valuable to own. It’s a tough gig to talk your laboratory up while also racing to find a coronavirus cure.

Some labs are making a heroic effort of this with funding secured in government grants and from prior successful drugs. However, weakening bull-bear relations show that any enthusiastic biotech lab can make a headline. If a biotech is deliberately hyping a cure while issuing new shares ‘at-the-market’ price (ATM) to raise funds, run or go short!

Investors should also be cognizant of the stage of research. If there’s a breakthrough in vitro, that means in a petri dish, not in a human (vivo). There’s also likely to be only one patented ‘cure,’ but dozens of testing tools (like Abbot’s toaster-size saliva searcher) and therapeutic treatments. This is good, but the fabled vaccine itself will have to pass through four sets of trials successfully before it can be sold. Investors are watching these;

Preclinical

Do mice, pigs, and monkeys keel over and die from the drug?

Phase I

Do 10 people get any embarrassing side-effects from the drug?

Phase II

Does the drug work on 200 people that actually have the virus?

Phase III

Will the drug work even better if the dosage is fine-tuned?

FDA Review

Will thousands of pages of data from these phases get stamped?

The approval pipeline can last between ten and twelve years, which is why it takes millions in cash burn before anything happens. However, the US Food and Drug Administration (FDA) is fast-tracking promising innovations amid this crisis.

Moderna’s well-publicized jab is in stage I, Pfizer’s candidate is in stage II, and the University of Melbourne has a vaccine in stage III. AstraZeneca would profit from distributing Oxford University’s phase III ‘ChAdOx1 nCoV-19,’ but there’s apparently not enough people catching the virus anymore for a large enough test group! 

In sum, this is an exciting trade. Some stocks are exploding on talk, others are getting fast-track approval on the down-low. It’s hard to tell real from fake, and there’s always an element of the unknown with hundreds of competitors in the mix. This space is moving fast, though, and assuming sound diversification; any investor can take a dip.

Share:
More Posts
The Crude Oil Bust 🛢

Surging global crude oil prices, driven by factors like OPEC+ production cuts have pushed U.S. West Texas Intermediate futures to over $95 per barrel.

Metaverse Returns 🤖

Meta, led by CEO Mark Zuckerberg, is intensifying its commitment to innovation in the Metaverse through the introduction of the Quest 3 VR headset.

Get your daily Invstr Crunch

Get the market news and updates you need, delivered to your inbox or available on our daily podcast.

Risk Disclosure:

Invstr is not a bank and banking services are provided by Vast Bank, N.A.

Brokerage and Banking services are currently only available to U.S. residents.

Invstr app and web services are provided by Invstr Ltd. Advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC) details of which can be obtained here. Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value.

Investing involves risk and can lead to losses. Past performance does not guarantee future results.

Invstr app and web services are provided by Invstr Ltd. Invstr+ advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC). Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value. Vast Bank N.A. a nationally chartered bank and member of the FDIC, provides the banking products, including the products and services related to digital asset accounts. As with any asset, the value of Digital assets can go up or down and there can be a substantial risk that you lose money buying or holding digital assets. You should carefully consider whether trading or holding Digital assets is suitable for you in light of your financial condition. Your digital account does not support wallet to wallet transferring of your digital assets (i.e. cryptocurrencies) outside the platform. Any Digital Assets in your digital asset account are not insured by any government entities, including but not limited to FDIC or SIPC. The Invstr Visa® Debit Card is issued by Vast Bank, N.A. pursuant to a license from Visa U.S.A Inc and may be used everywhere Visa debit cards are accepted. Invstr Ltd, Invstr Financial LLC and Invstr Securities Ltd are subsidiaries of Marketspringpad Holdings (collectively “Invstr”) and Invstr is solely responsible for the application services and website content.

Watchlists provided when users first access the service are not a recommendation to invest. Instead they are provided to help users better navigate the service. Users are free to edit and create their own watchlists. From time to time, Invstr will suggest instruments solely based on an individual’s interest and the interest levels of the Invstr community. The statistical and portfolio builder models generated by Invstr do not reflect actual investment results and are not guarantees of future results. Comments provided by Invstr leaders, influencers or members of the Invstr Community are not recommendations and should not be construed as such. Invstr does not endorse the content or the positions posted by them. Their investment approach, and that of the models provided by Invstr, may be different from yours and may not be appropriate for you.